{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T09:35:54Z","timestamp":1790501754023,"version":"4.1.0"},"reference-count":64,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2018,6,20]],"date-time":"2018-06-20T00:00:00Z","timestamp":1529452800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006501","name":"Cystic Fibrosis Foundation Therapeutics","doi-asserted-by":"publisher","award":["Hodges15XX0"],"award-info":[{"award-number":["Hodges15XX0"]}],"id":[{"id":"10.13039\/100006501","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006501","name":"Cystic Fibrosis Foundation Therapeutics","doi-asserted-by":"publisher","award":["Conlon15XX0"],"award-info":[{"award-number":["Conlon15XX0"]}],"id":[{"id":"10.13039\/100006501","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0199573","type":"journal-article","created":{"date-parts":[[2018,6,20]],"date-time":"2018-06-20T17:59:16Z","timestamp":1529517556000},"page":"e0199573","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":64,"title":["A G542X cystic fibrosis mouse model for examining nonsense mutation directed therapies"],"prefix":"10.1371","volume":"13","author":[{"given":"Daniel R.","family":"McHugh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miarasa S.","family":"Steele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana M.","family":"Valerio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Miron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel J.","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"LePage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald A.","family":"Conlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calvin U.","family":"Cotton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell L.","family":"Drumm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3332-9024","authenticated-orcid":true,"given":"Craig A.","family":"Hodges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,6,20]]},"reference":[{"issue":"1","key":"ref1","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1080\/01926230601060025","article-title":"Cystic fibrosis and other respiratory diseases of impaired mucus clearance","volume":"35","author":"A Livraghi","year":"2007","journal-title":"Toxicologic pathology"},{"issue":"18","key":"ref2","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.1113\/jphysiol.2012.240861","article-title":"Does epithelial sodium channel hyperactivity contribute to cystic fibrosis lung disease?","volume":"591","author":"CA Hobbs","year":"2013","journal-title":"The Journal of physiology"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1164\/rccm.201011-1892OC","article-title":"Infection, inflammation, and lung function decline in infants with cystic fibrosis","volume":"184","author":"N Pillarisetti","year":"2011","journal-title":"American journal of respiratory and critical care medicine"},{"issue":"Suppl 2","key":"ref4","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/j.jcf.2017.06.011","article-title":"Pancreatic insufficiency in Cystic Fibrosis","volume":"16","author":"VK Singh","year":"2017","journal-title":"J Cyst Fibros"},{"issue":"9","key":"ref5","doi-asserted-by":"crossref","first-page":"a009753","DOI":"10.1101\/cshperspect.a009753","article-title":"The cystic fibrosis intestine","volume":"3","author":"RC De Lisle","year":"2013","journal-title":"Cold Spring Harbor perspectives in medicine"},{"issue":"Suppl 2","key":"ref6","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/S1569-1993(11)60005-2","article-title":"Guidelines for the diagnosis and management of distal intestinal obstruction syndrome in cystic fibrosis patients","volume":"10","author":"C Colombo","year":"2011","journal-title":"J Cyst Fibros"},{"issue":"8471","key":"ref7","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0140-6736(86)91894-5","article-title":"Treatment of distal intestinal obstruction syndrome in cystic fibrosis with a balanced intestinal lavage solution","volume":"1","author":"GJ Cleghorn","year":"1986","journal-title":"Lancet (London, England)"},{"issue":"5","key":"ref8","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/ng.2221","article-title":"Multiple apical plasma membrane constituents are associated with susceptibility to meconium ileus in individuals with cystic fibrosis","volume":"44","author":"L Sun","year":"2012","journal-title":"Nature genetics"},{"issue":"3","key":"ref9","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/ajcn\/69.3.531","article-title":"Comparison of growth status of patients with cystic fibrosis between the United States and Canada","volume":"69","author":"HC Lai","year":"1999","journal-title":"Am J Clin Nutr"},{"issue":"5\u20136","key":"ref10","first-page":"393","article-title":"Growth failure in children with cystic fibrosis","volume":"25","author":"A Scaparrotta","year":"2012","journal-title":"Journal of pediatric endocrinology & metabolism: JPEM"},{"issue":"2","key":"ref11","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/0884533614555234","article-title":"Growth failure and nutrition considerations in chronic childhood wasting diseases","volume":"30","author":"UG Kyle","year":"2015","journal-title":"Nutrition in clinical practice: official publication of the American Society for Parenteral and Enteral Nutrition"},{"issue":"3","key":"ref12","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/BF02254769","article-title":"Severe phenotype in mice with termination mutation in exon 2 of cystic fibrosis gene","volume":"21","author":"P Hasty","year":"1995","journal-title":"Somat Cell Mol Genet"},{"issue":"10","key":"ref13","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1093\/hmg\/2.10.1561","article-title":"A severe phenotype in mice with a duplication of exon 3 in the cystic fibrosis locus","volume":"2","author":"WK O'Neal","year":"1993","journal-title":"Hum Mol Genet"},{"issue":"9","key":"ref14","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00109-002-0363-1","article-title":"Aminoglycoside suppression of a premature stop mutation in a Cftr-\/- mouse carrying a human CFTR-G542X transgene","volume":"80","author":"M Du","year":"2002","journal-title":"Journal of molecular medicine (Berlin, Germany)"},{"issue":"11","key":"ref15","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.molmed.2012.09.008","article-title":"Sense from nonsense: therapies for premature stop codon diseases","volume":"18","author":"L Bidou","year":"2012","journal-title":"Trends in molecular medicine"},{"issue":"Pt 5","key":"ref16","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1046\/j.1469-1809.2003.00028.x","article-title":"The phenotypic consequences of CFTR mutations","volume":"67","author":"RK Rowntree","year":"2003","journal-title":"Annals of human genetics"},{"issue":"18","key":"ref17","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"BW Ramsey","year":"2011","journal-title":"N Engl J Med"},{"issue":"44","key":"ref18","doi-asserted-by":"crossref","first-page":"18825","DOI":"10.1073\/pnas.0904709106","article-title":"Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770","volume":"106","author":"F Van Goor","year":"2009","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"19","key":"ref19","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1091\/mbc.e13-05-0240","article-title":"VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1","volume":"24","author":"HY Ren","year":"2013","journal-title":"Molecular biology of the cell"},{"issue":"3","key":"ref20","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR","volume":"373","author":"CE Wainwright","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"ref21","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nm0496-467","article-title":"Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations","volume":"2","author":"M Howard","year":"1996","journal-title":"Nat Med"},{"issue":"7140","key":"ref22","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nature05756","article-title":"PTC124 targets genetic disorders caused by nonsense mutations","volume":"447","author":"EM Welch","year":"2007","journal-title":"Nature"},{"issue":"4","key":"ref23","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1165\/rcmb.2013-0282OC","article-title":"Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftor","volume":"50","author":"X Xue","year":"2014","journal-title":"American journal of respiratory cell and molecular biology"},{"issue":"6","key":"ref24","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/ana.22024","article-title":"Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy","volume":"67","author":"V Malik","year":"2010","journal-title":"Annals of neurology"},{"issue":"10","key":"ref25","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1164\/rccm.201001-0137OC","article-title":"Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis","volume":"182","author":"I Sermet-Gaudelus","year":"2010","journal-title":"American journal of respiratory and critical care medicine"},{"issue":"15","key":"ref26","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1056\/NEJMoa022170","article-title":"Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations","volume":"349","author":"M Wilschanski","year":"2003","journal-title":"N Engl J Med"},{"issue":"10101","key":"ref27","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0140-6736(17)31611-2","article-title":"Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"CM McDonald","year":"2017","journal-title":"Lancet (London, England)"},{"issue":"10","key":"ref28","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1681\/ASN.2005101124","article-title":"A non-nephrotoxic gentamicin congener that retains antimicrobial efficacy","volume":"17","author":"RM Sandoval","year":"2006","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"7","key":"ref29","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S2213-2600(14)70100-6","article-title":"Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial","volume":"2","author":"E Kerem","year":"2014","journal-title":"The Lancet Respiratory medicine"},{"issue":"23","key":"ref30","doi-asserted-by":"crossref","first-page":"10730","DOI":"10.1073\/pnas.88.23.10730","article-title":"Toward an animal model of cystic fibrosis: targeted interruption of exon 10 of the cystic fibrosis transmembrane regulator gene in embryonic stem cells","volume":"88","author":"BH Koller","year":"1991","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"5073","key":"ref31","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1126\/science.257.5073.1083","article-title":"An animal model for cystic fibrosis made by gene targeting","volume":"257","author":"JN Snouwaert","year":"1992","journal-title":"Science"},{"issue":"12","key":"ref32","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1136\/jmg.28.12.878","article-title":"A cystic fibrosis patient with the nonsense mutation G542X and the splice site mutation 1717\u20131","volume":"28","author":"M Schloesser","year":"1991","journal-title":"Journal of medical genetics"},{"issue":"9","key":"ref33","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nbt.2647","article-title":"DNA targeting specificity of RNA-guided Cas9 nucleases","volume":"31","author":"PD Hsu","year":"2013","journal-title":"Nat Biotechnol"},{"issue":"10","key":"ref34","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1101\/gr.176701.114","article-title":"OutKnocker: a web tool for rapid and simple genotyping of designer nuclease edited cell lines","volume":"24","author":"JL Schmid-Burgk","year":"2014","journal-title":"Genome Res"},{"issue":"5","key":"ref35","doi-asserted-by":"crossref","first-page":"L1173","DOI":"10.1152\/ajplung.2001.281.5.L1173","article-title":"Examining basal chloride transport using the nasal potential difference response in a murine model","volume":"281","author":"KG Brady","year":"2001","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"10","key":"ref36","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/dvg.20433","article-title":"Generation of a conditional null allele for Cftr in mice","volume":"46","author":"CA Hodges","year":"2008","journal-title":"Genesis"},{"issue":"5","key":"ref37","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1053\/j.gastro.2011.07.050","article-title":"Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium","volume":"141","author":"T Sato","year":"2011","journal-title":"Gastroenterology"},{"issue":"10","key":"ref38","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1128\/IAI.00639-16","article-title":"Intestinal Enteroids Model Guanylate Cyclase C-Dependent Secretion Induced by Heat-Stable Enterotoxins","volume":"84","author":"AM Pattison","year":"2016","journal-title":"Infection and immunity"},{"issue":"7","key":"ref39","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/nm.3201","article-title":"A functional CFTR assay using primary cystic fibrosis intestinal organoids","volume":"19","author":"JF Dekkers","year":"2013","journal-title":"Nat Med"},{"issue":"5","key":"ref40","first-page":"L1065","article-title":"In vivo activation of CFTR-dependent chloride transport in murine airway epithelium by CNP","volume":"273","author":"TJ Kelley","year":"1997","journal-title":"The American journal of physiology"},{"issue":"5","key":"ref41","doi-asserted-by":"crossref","first-page":"L944","DOI":"10.1152\/ajplung.00387.2003","article-title":"Role of Cftr genotype in the response to chronic Pseudomonas aeruginosa lung infection in mice","volume":"287","author":"AM van Heeckeren","year":"2004","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"5073","key":"ref42","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1126\/science.257.5073.1125","article-title":"Defective epithelial chloride transport in a gene-targeted mouse model of cystic fibrosis","volume":"257","author":"LL Clarke","year":"1992","journal-title":"Science"},{"issue":"4","key":"ref43","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1172\/JCI118253","article-title":"A mouse model for the delta F508 allele of cystic fibrosis","volume":"96","author":"BG Zeiher","year":"1995","journal-title":"J Clin Invest"},{"issue":"Suppl 2","key":"ref44","doi-asserted-by":"crossref","first-page":"S152","DOI":"10.1016\/S1569-1993(11)60020-9","article-title":"Mouse models of cystic fibrosis: phenotypic analysis and research applications","volume":"10","author":"M Wilke","year":"2011","journal-title":"J Cyst Fibros"},{"issue":"3","key":"ref45","doi-asserted-by":"crossref","first-page":"G528","DOI":"10.1152\/ajpgi.00052.2011","article-title":"Cystic fibrosis growth retardation is not correlated with loss of Cftr in the intestinal epithelium","volume":"301","author":"CA Hodges","year":"2011","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"5","key":"ref46","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/j.1460-2075.1996.tb00432.x","article-title":"Cystic fibrosis mice carrying the missense mutation G551D replicate human genotype-phenotype correlations","volume":"15","author":"SJ Delaney","year":"1996","journal-title":"Embo J"},{"issue":"11","key":"ref47","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1016\/j.bmc.2010.03.060","article-title":"Repairing faulty genes by aminoglycosides: development of new derivatives of geneticin (G418) with enhanced suppression of diseases-causing nonsense mutations","volume":"18","author":"I Nudelman","year":"2010","journal-title":"Bioorganic & medicinal chemistry"},{"issue":"7","key":"ref48","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/hmg\/ddp030","article-title":"Translational readthrough by the aminoglycoside geneticin (G418) modulates SMN stability in vitro and improves motor function in SMA mice in vivo","volume":"18","author":"CR Heier","year":"2009","journal-title":"Hum Mol Genet"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1146\/annurev-genom-091212-153527","article-title":"Therapeutics based on stop codon readthrough","volume":"15","author":"KM Keeling","year":"2014","journal-title":"Annu Rev Genomics Hum Genet"},{"issue":"5","key":"ref50","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1159\/000343086","article-title":"Readthrough strategies for therapeutic suppression of nonsense mutations in inherited metabolic disease","volume":"3","author":"B Perez","year":"2012","journal-title":"Mol Syndromol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1741-7015-5-5","article-title":"In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study","volume":"5","author":"I Sermet-Gaudelus","year":"2007","journal-title":"BMC Med"},{"issue":"13","key":"ref52","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1073\/pnas.1620982114","article-title":"Gentamicin B1 is a minor gentamicin component with major nonsense mutation suppression activity","volume":"114","author":"A Baradaran-Heravi","year":"2017","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"6","key":"ref53","doi-asserted-by":"crossref","first-page":"e1001593","DOI":"10.1371\/journal.pbio.1001593","article-title":"A lack of premature termination codon read-through efficacy of PTC124 (Ataluren) in a diverse array of reporter assays","volume":"11","author":"SP McElroy","year":"2013","journal-title":"PLoS Biol"},{"issue":"6","key":"ref54","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1073\/pnas.0711795105","article-title":"PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model","volume":"105","author":"M Du","year":"2008","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"9640","key":"ref55","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0140-6736(08)61168-X","article-title":"Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial","volume":"372","author":"E Kerem","year":"2008","journal-title":"Lancet (London, England)"},{"issue":"11","key":"ref56","doi-asserted-by":"crossref","first-page":"e0187930","DOI":"10.1371\/journal.pone.0187930","article-title":"Optimized approach for the identification of highly efficient correctors of nonsense mutations in human diseases","volume":"12","author":"H Benhabiles","year":"2017","journal-title":"PLoS One"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1750-1172-7-58","article-title":"Rescue of nonsense mutations by amlexanox in human cells","volume":"7","author":"S Gonzalez-Hilarion","year":"2012","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"ref58","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1177\/2472630317692561","article-title":"High-Throughput Screening for Readthrough Modulators of CFTR PTC Mutations","volume":"22","author":"F Liang","year":"2017","journal-title":"SLAS Technol"},{"issue":"9","key":"ref59","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1164\/rccm.201601-0154OC","article-title":"Discovery of Clinically Approved Agents That Promote Suppression of Cystic Fibrosis Transmembrane Conductance Regulator Nonsense Mutations","volume":"194","author":"V Mutyam","year":"2016","journal-title":"American journal of respiratory and critical care medicine"},{"issue":"4","key":"ref60","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.cell.2013.04.025","article-title":"One-step generation of mice carrying mutations in multiple genes by CRISPR\/Cas-mediated genome engineering","volume":"153","author":"H Wang","year":"2013","journal-title":"Cell"},{"issue":"9","key":"ref61","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nbt.2623","article-title":"High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells","volume":"31","author":"Y Fu","year":"2013","journal-title":"Nat Biotechnol"},{"issue":"6","key":"ref62","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nmeth.3408","article-title":"Off-target mutations are rare in Cas9-modified mice","volume":"12","author":"V Iyer","year":"2015","journal-title":"Nat Methods"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"34703","DOI":"10.1038\/srep34703","article-title":"Exome sequencing in the knockin mice generated using the CRISPR\/Cas system","volume":"6","author":"K Nakajima","year":"2016","journal-title":"Sci Rep"},{"key":"ref64","article-title":"Translational research to enable personalized treatment of cystic fibrosis","author":"MC Hagemeijer","year":"2017","journal-title":"J Cyst Fibros"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0199573","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T16:27:53Z","timestamp":1720369673000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0199573"}},"subtitle":[],"editor":[{"given":"Alfred S.","family":"Lewin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,6,20]]},"references-count":64,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,6,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0199573","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,20]]}}}